Food and Drug Administration (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Food and Drug Administration" in German language version.

refsWebsite

Global rank German rank

8fda.gov

447^th place

751^st place

5doi.org

2^nd place

3^rd place

4zdb-katalog.de

123^rd place

6^th place

2nih.gov

4^th place

7^th place

2jamanetwork.com

2,650^th place

1,472^nd place

1deutsche-apotheker-zeitung.de

low place

797^th place

1independent.org

low place

1loc.gov

70^th place

314^th place

1govtrackus.s3.amazonaws.com

low place

1lincolnproject.us

low place

1nytimes.com

7^th place

19^th place

1theconversation.com

928^th place

2,002^nd place

1science.org

1,160^th place

2,116^th place

1propublica.org

3,281^st place

2,830^th place

deutsche-apotheker-zeitung.de

H. Feldwisch-Drentrup: EMA und FDA stärken Zusammenarbeit. In: DAZ.online. 3. März 2017, abgerufen am 5. Januar 2020.

doi.org

Curt D. Furberg, Arthur A. Levin, Peter A. Gross: The FDA and Drug Safety. In: Archives of Internal Medicine. Band 166, Nr. 18, 9. Oktober 2006, S. 1938–1942, doi:10.1001/archinte.166.18.1938 (englisch).
Lisa M. Schwartz, Steven Woloshin: Communicating uncertainties about prescription drugs to the public: a national randomized trial. In: Archives of Internal Medicine. Band 171, Nr. 16, 12. September 2011, ISSN 1538-3679, S. 1463–1468, doi:10.1001/archinternmed.2011.396, PMID 21911629.
Tito Fojo, Sham Mailankody, Andrew Lo: Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture. In: JAMA Otolaryngology–Head & Neck Surgery. Band 140, Nr. 12, 1. Dezember 2014, ISSN 2168-6181, S. 1225, doi:10.1001/jamaoto.2014.1570 (jamanetwork.com [abgerufen am 12. August 2022]).
Aviv Ladanie, Andreas M. Schmitt, Benjamin Speich, Florian Naudet, Arnav Agarwal: Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. In: JAMA Network Open. Band 3, Nr. 11, 10. November 2020, ISSN 2574-3805, S. e2024406, doi:10.1001/jamanetworkopen.2020.24406, PMID 33170262 (jamanetwork.com [abgerufen am 12. August 2022]).
Daniel Tobias Michaeli, Thomas Michaeli: Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021. In: Journal of Clinical Oncology. 3. August 2022, ISSN 0732-183X, S. JCO.22.00535, doi:10.1200/JCO.22.00535.

fda.gov

Distribution of Full Time Equivalent (FTE) Employment by Program. fda.gov, abgerufen am 5. März 2014. (PDF-Datei, 469 kB, englisch).
Janet Woodcock M.D., Commissioner of Food and Drugs. fda.gov, abgerufen am 29. März 2021 (englisch).
FDA Organization. fda.gov, abgerufen am 31. Juli 2017 (englisch).
Mutual Recognition Agreement (MRA). In: www.fda.gov. 5. August 2020, abgerufen am 5. Januar 2020.
Centennial of FDA. fda.gov (englisch).
The Kefauver-Harris Amendments. fda.gov (englisch).
US Dietary Supplement Health and Education Act of 1994. fda.gov (englisch).
FDA Organization Chart fda.gov, abgerufen am 15. Juli 2021 (englisch).

govtrackus.s3.amazonaws.com

Statutes at Large: 57th Congress. Session 1, Chapter 1378, 1902 (PDF-Datei, englisch).

independent.org

Ronald Hamowy: Medical Disasters and the Growth of the FDA. Independent Policy Reports, The Independent Institute, 2010 (PDF-Datei, englisch).

jamanetwork.com

archotol.jamanetwork.com

Tito Fojo, Sham Mailankody, Andrew Lo: Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture. In: JAMA Otolaryngology–Head & Neck Surgery. Band 140, Nr. 12, 1. Dezember 2014, ISSN 2168-6181, S. 1225, doi:10.1001/jamaoto.2014.1570 (jamanetwork.com [abgerufen am 12. August 2022]).

jamanetwork.com

Aviv Ladanie, Andreas M. Schmitt, Benjamin Speich, Florian Naudet, Arnav Agarwal: Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. In: JAMA Network Open. Band 3, Nr. 11, 10. November 2020, ISSN 2574-3805, S. e2024406, doi:10.1001/jamanetworkopen.2020.24406, PMID 33170262 (jamanetwork.com [abgerufen am 12. August 2022]).

lincolnproject.us

It’s out of Contol. The Lincoln Project (englisch)

loc.gov

Statutes at Large: 57th Congress. Session 1, Chapter 1378, 1902 (PDF-Datei, englisch).

nih.gov

ncbi.nlm.nih.gov

Lisa M. Schwartz, Steven Woloshin: Communicating uncertainties about prescription drugs to the public: a national randomized trial. In: Archives of Internal Medicine. Band 171, Nr. 16, 12. September 2011, ISSN 1538-3679, S. 1463–1468, doi:10.1001/archinternmed.2011.396, PMID 21911629.
Aviv Ladanie, Andreas M. Schmitt, Benjamin Speich, Florian Naudet, Arnav Agarwal: Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. In: JAMA Network Open. Band 3, Nr. 11, 10. November 2020, ISSN 2574-3805, S. e2024406, doi:10.1001/jamanetworkopen.2020.24406, PMID 33170262 (jamanetwork.com [abgerufen am 12. August 2022]).

nytimes.com

The lost month: How a failure to test blinded the U.S. to Covid-19. nytimes.com, 28. März 2020 (englisch)

propublica.org

Caroline Chen: FDA Repays Industry by Rushing Risky Drugs to Market. Abgerufen am 16. Mai 2022 (englisch).

science.org

FDA's revolving door: Companies often hire agency staffers who managed their successful drug reviews. Abgerufen am 16. Mai 2022 (englisch).

theconversation.com

C. Michael White: Why is the FDA funded in part by the companies it regulates? Abgerufen am 16. Mai 2022 (englisch).

zdb-katalog.de

Lisa M. Schwartz, Steven Woloshin: Communicating uncertainties about prescription drugs to the public: a national randomized trial. In: Archives of Internal Medicine. Band 171, Nr. 16, 12. September 2011, ISSN 1538-3679, S. 1463–1468, doi:10.1001/archinternmed.2011.396, PMID 21911629.
Tito Fojo, Sham Mailankody, Andrew Lo: Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture. In: JAMA Otolaryngology–Head & Neck Surgery. Band 140, Nr. 12, 1. Dezember 2014, ISSN 2168-6181, S. 1225, doi:10.1001/jamaoto.2014.1570 (jamanetwork.com [abgerufen am 12. August 2022]).
Aviv Ladanie, Andreas M. Schmitt, Benjamin Speich, Florian Naudet, Arnav Agarwal: Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. In: JAMA Network Open. Band 3, Nr. 11, 10. November 2020, ISSN 2574-3805, S. e2024406, doi:10.1001/jamanetworkopen.2020.24406, PMID 33170262 (jamanetwork.com [abgerufen am 12. August 2022]).
Daniel Tobias Michaeli, Thomas Michaeli: Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021. In: Journal of Clinical Oncology. 3. August 2022, ISSN 0732-183X, S. JCO.22.00535, doi:10.1200/JCO.22.00535.